Ophthotech Corp (OPHT) Tops Q2 EPS by 2c

Ophthotech Corp (NASDAQ: OPHT) reported Q2 EPS of ($0.37), $0.02 better than the analyst estimate of ($0.39).

“During the first half of the year, we continued implementing our strategy to broaden and advance our ophthalmic portfolio as we enter the emerging field of gene therapy by securing collaborations with three leading academic institutions, and continued advancing our therapeutic portfolio with Zimura®,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech. “Looking ahead to the remainder of 2018, we expect to report data for our Phase 2a clinical trial for Zimura combination therapy with anti-VEGF in wet-age related macular degeneration (AMD), complete recruitment for our Phase 2b clinical trial for Zimura monotherapy in geographic atrophy secondary to dry AMD and potentially enter into new opportunities to further expand our portfolio in both therapeutics and gene therapies for retinal diseases.”

For earnings history and earnings-related data on Ophthotech Corp (OPHT) click here.

You May Also Be Interested In

• Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
• First Bank (FRBA) Tops Q1 EPS by 7c
• Cadence Design Systems (CDNS) Tops Q1 EPS by 4c, provides guidance